Kristian Le Vay is an expert scientist at Coriolis Pharma focussing on novel methods to assess the developability of monoclonal antibodies and other biotherapeutics. Kristian studied chemistry at the University of Bristol, UK, where he also completed his PhD in functional nanomaterials and biochemistry in 2017. He researched the synthesis and stability of complex artificial enzyme systems and specialized in the biophysical characterization of proteins. He then moved to Germany, investigating RNA catalysis and stability as a postdoctoral researcher at the Max Planck Institute for Biochemistry, before joining Coriolis in 2022.